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Abstract
Background: Tuberous sclerosis complex (TSC) is a genetic disorder affecting about 1 in 6000 people and is
characterised by the development of tumours in many organs, including the skin and kidneys, and by a range of
neurological and neuropsychiatric manifestations. TSC-associated neuropsychiatric disorders (TAND) occur in the
majority of those with TSC, and they have a significant impact on patients and their families, given the everyday
impact of TAND on education, employment, family and social life. The potential benefits of better treatment for
TAND therefore include reduction in health care demands and wider benefits for patients and their carers.
Methods/design: We have planned a single-centre, two-arm, individually randomised, phase II, double-blind,
placebo-controlled trial of everolimus versus placebo in the treatment of neurocognitive problems in patients with
tuberous sclerosis. Everolimus is a licensed medicine in this patient group, but for a different target of effect. The
present trial is a proof-of-principle study developed to provide effect size estimates which may be used to inform
the design of subsequent trials. Forty-eight patients aged 16–60 years with tuberous sclerosis who have an IQ >60
and a significant deficit (at least −2 SD) in one or more primary outcome measures will be randomly allocated in
a ratio of 2:1 to receive everolimus or placebo, respectively. Participants will be assessed for eligibility and then be
started on study medication 4 weeks later. They will then be randomised and receive placebo or everolimus for
24 weeks. Neurocognitive and safety assessments will be carried out at baseline and weeks 4, 12, 24 and 36.
Discussion: This study is designed to determine the effect sizes of treatment with everolimus or placebo for 6 months
on specific neurocognitive functions—recall memory (verbal and non-verbal) and executive function—in people
affected by TSC who have significant deficits in these functions. These data will provide new evidence to determine
whether larger-scale trials are indicated and to explore suitable outcome measures and analytical methods for
neurocognitive trial design.
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Background
Tuberous sclerosis complex (TSC) is a rare genetic dis-
order affecting approximately 1 in 6000 people and is
caused by mutations in the TSC1 or TSC2 gene. It is
characterised by the development of benign tumours in
many organs, including the skin, kidneys, heart, eyes,
lungs and brain. Brain involvement can lead to seizures,
neurocognitive deficits and behavioural and develop-
mental disorders. TSC-associated neuropsychiatric disor-
ders (TAND) occur in the majority of those with TSC,
even in the approximately 50 % of patients with normal
IQ (>70) [1–3], and they are rated as the most signifi-
cant disease manifestations by patients and families
because of their everyday impact on education, employ-
ment, family and social life [4]. Better treatment op-
tions for TAND have the potential to both reduce
health care demands and offer wider benefits for pa-
tients and their carers.
In the past, it was thought that the cognitive, behav-
ioural and neurological manifestations of TSC might be
entirely attributable to tubers—characteristic areas of
cerebral cortex or sub-cortical white matter—which
occur in most people with TSC. However, recent mo-
lecular and cellular insights indicate that the intracellular
consequences of TSC1 and TSC2 gene mutations may
also play a direct and potentially reversible role [5]. New
imaging techniques have revealed subtle abnormalities
of brain microstructure in otherwise normal-appearing
white matter [6]. The TSC1 and TSC2 proteins (hamartin
and tuberin, respectively) form a complex that acts to sup-
press mammalian target of rapamycin complex 1
(mTORC1) signalling; thus, disruption of the TSC1-TSC2
complex (as a consequence of mutations in either TSC1
or TSC2) leads to excessive mTORC1 signalling. The
effects of this have been demonstrated in immunohisto-
chemical and immunoblotting studies that have shown
activation of the downstream effectors of mTORC1, S6
kinase and phospho-S6 in tuberous sclerosis lesions in
both pre-clinical models and patients [7]. In pre-clinical tri-
als, treatment with mTORC1 inhibitors shrank or pre-
vented kidney tumours, improved memory and learning,
stopped or prevented epilepsy, and improved survival in
transgenic Tsc1- and Tsc2-mutant mice [8–10]. Published
findings from the Tsc2 study [9] came at a time which
served to reinforce interest in the neurocognitive trials in
humans. Clinical trials using the mTORC1 inhibitors siroli-
mus and everolimus have demonstrated significant reduc-
tions in brain and kidney tumour volume, along with
acceptable safety and tolerability, in patients with tuberous
sclerosis [11–15]. These findings led to licensing of everoli-
mus for these indications in the United States and Europe.
In the study of Davies et al. [13, 14], we also moni-
tored memory, learning and executive function as sec-
ondary endpoints. During the treatment period, patients
with tuberous sclerosis showed improvements in visuo-
spatial and verbal recall memory and in executive func-
tion, but not in recognition memory tasks. However,
because the trial was not a randomised controlled trial
and involved very small numbers of patients, we could not
distinguish learning effects due to repeat administration
(so-called practice effects) of the tests from drug effects.
Up until 14 September 2015, a total of 11 controlled tri-
als of investigational medicinal products investigating
mTORC1 inhibitors in patients with tuberous sclerosis
were listed at ClinicalTrials.gov. Several are completed or
no longer recruiting. Most are investigating tumour-
related outcomes. All are using everolimus or sirolimus
(rapamycin). Researchers in one current phase II, non-
randomised, open-label trial are investigating the efficacy
of everolimus in TSC-associated seizures (NCT01070316).
A signal-seeking, randomised, placebo-controlled trial of
everolimus for neurocognitive problems in young people
with TSC has been completed in the United States, but
the results are not yet reported (NCT01289912) [3].
The present trial, TRON, will be an investigation of
everolimus in relation to neurocognitive function in
adult patients with TSC. It will determine effect sizes to
provide evidence for whether larger trials for this indica-
tion are appropriate. In contrast to the U.S. study
(NCT01289912), it will be focused on adult patients who
do not have active seizures or who have well-controlled
seizures as well as some degree of cognitive impairment.
TAND is multi-level with varying cognitive, behavioural
and psychiatric manifestations [3]. In order to differenti-
ate between these, the principal level investigated here
through the primary outcomes is the ‘neuropsycho-
logical’ level, which will be referred to as neurocognition.
Methods/design
Study design
This is a single-centre, two-arm, individually rando-
mised, phase II, double-blind, placebo-controlled trial of
everolimus versus placebo (allocation ratio of 2:1, re-
spectively) in the treatment of neurocognitive problems
in patients with TSC. Patients are treated in an out-
patient setting at a specialist centre in a large teaching
hospital. The present trial is a proof-of-principle study
designed to provide effect size estimates which may be
used to inform the design of subsequent trials (Fig. 1).
Ethical approval was granted by the Wales Research Eth-
ics Committee on 9 November 2011. A Standard Proto-
col Items: Recommendations for Interventional Trials
(SPIRIT) checklist is provided as Additional file 1.
Research objectives
Primary objective
The primary objective is to determine the effect sizes of
treatment with everolimus or placebo for 6 months on
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recall memory and executive function in people with tu-
berous sclerosis.
Secondary objective
The secondary objective is to assess the effects of treat-
ment with everolimus or placebo for 6 months on wider
aspects of neurocognitive functioning, seizures and daily
life in people with tuberous sclerosis and to assess safety
using the National Cancer Institute Common Termin-
ology Criteria for Adverse Events (CTCAE) version 4.0.
Exploratory objective
A further exploratory objective is to determine whether
an effect of treatment with everolimus or placebo is
detectable at 1 month and 3 months after the start of
therapy to establish whether any early markers of
change are present.
Fig. 1 TRON trial design flowchart indicating anticipated patient numbers and dropout. CRN Clinical Research Network, DTI MR diffusion tensor imaging
magnetic resonance imaging, PIS patient information sheet, TSA Tuberous Sclerosis Association
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Sample size determination
The sample size has been calculated on the basis of
Fleming’s single-stage procedure [16] and considers the
sample size required to assess the change in the experi-
mental group. The control group provides evidence of
the learning effect due to repeated assessments. The
proposed study seeks to determine effect sizes in relation
to the primary outcome measures to enable informed
designing of subsequent larger studies. This study is
therefore not powered for formal statistical comparison
of placebo and study drug groups.
We estimate the learning effect (i.e., the proportion of
patients whose memory function improves due to famil-
iarity with the assessments) to be slightly less than 0.15.
A proportion of less than 0.15 in the intervention group
would therefore indicate that the intervention (everoli-
mus in the treatment of neurocognitive problems in tu-
berous sclerosis) does not warrant further investigation.
A proportion of at least 0.35 would provide sufficient
evidence for further investigation of this intervention.
Values between these would be discussed in depth by
members of the trial team.
Therefore, to test the null hypothesis that the propor-
tion of patients in the intervention group who improve
their memory function by 1 SD is at most 0.15 against
the alternative hypothesis that the proportion of patients
in the intervention group who improve their memory
function by 1 SD is at least 0.35, with 80 % power and a
one-sided α of 0.05, we require a total sample size of 48
(i.e., 32 who receive the intervention and 16 control sub-
jects). This sample size is inflated to allow for 20 % loss
to follow-up.
Recruitment
Patients aged between 16 and 60 years with tuberous
sclerosis will be invited to take part in the trial. The trial
will be advertised through the Tuberous Sclerosis
Association (TSA) via its website, a regular update
e-magazine and a magazine that is mailed to TSA
members (approximately 1000 families). Clinical ge-
neticists throughout the United Kingdom will be
made aware of the study through the Clinical Genet-
ics Clinical Research Network, and the study has
been adopted by National Institute for Health Re-
search via this network. Awareness of the trial will
be raised at appropriate conferences. Genetics ser-
vices will be approached to act as patient identifi-
cation centres. Patients attending TSA-supported
tuberous sclerosis clinics will also be notified of the
trial.
Screening for eligibility
Entry into the study is carried out through a two-stage
process. Those who are likely to be eligible will be
offered a screening appointment (visit 1), at which fully
informed written consent will be obtained. A screening
assessment to confirm or refute eligibility will include a
full medical history; current medications; physical exam-
ination; blood, urine and (for females) pregnancy tests;
and neurocognitive tests. Patients must fulfil all of the
inclusion criteria and none of the exclusion criteria, as
detailed in Table 1.
Informed consent
Eligible patients may only be included in the study after
providing written (witnessed, where required by law or
regulation), informed consent, or, if incapable of doing
so, after such consent has been provided by a legally ac-
ceptable representative of the patient. Informed consent
will also be taken from the individual who accompanies a
patient to the assessment visits – whether that is their
carer, parent, partner or someone who knows them well –
as they will be asked to complete assessments at various
time points.
Randomisation and blinding
Randomisation will be carried out by the South East
Wales Trials Unit, using a computer-generated alloca-
tion sequence according to a 2:1 for intervention-to-
control ratio. The participant’s unique identification
number and allocation will be double-blinded so that
the participant, clinician, research psychologist and trial
statistician will not know to which treatment group the
participant has been allocated.
The trial pharmacy will hold details of patients’ treat-
ment allocations and can maintain 24-h cover to un-
blind in case of an overdose. For all other emergencies,
physicians should stop the drug (as unblinding would
not affect symptom management) and contact a mem-
ber of the clinical team as soon as possible afterwards.
For non-emergencies, the treating physician should
contact a trial clinician to discuss the need to unblind
or stop treatment.
Treatment
The daily investigational drug dose will be 5 mg of
everolimus administered for 6 months as two oral 2.5-
mg tablets once daily, but with adjustment to achieve
trough blood levels of 3–10 ng/ml. A lower dose (as
compared with the dose used to treat renal angiomyoli-
poma [AML]) has been chosen to mitigate side effects,
whose frequency and severity may be dose-related. The
appearance of placebo medication will be identical to
that of active drug to maintain the blinding. Pharmacy
staff will be unblinded and will not reveal treatment allo-
cation to anyone without permission from a member of
the clinical team or investigational team. Trough blood
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levels of everolimus will be measured at each study visit
and reported to the study doctor through the trials unit.
Mock levels for patients on placebo will also be reported
in proportion to those for patients on active drug. The
study clinicians will then make decisions regarding dos-
age changes.
Treatment will be dispensed at visits 2, 4 and 6.
Patients will take the medication at the study site at
visits 3–7 and at home on all other treatment days.
Compliance will be monitored by pill counts at each
visit. Samples for drug levels (pharmacokinetic assess-
ments) will be taken at visits 3–7 inclusive.
Table 1 TRON study entry criteria
Inclusion criteria Exclusion criteriaa
1 Definite TSC based on current clinical criteria [29] Prior treatment with an mTOR inhibitor
2 Male or female aged 16–60 years Investigational agent taken <30 days prior to randomisation
3 IQ >60 as determined by using WASI and able to participate in
direct neuropsychological tests
Surgery in last 2 months
4 A score falling on, or below, the 5th percentile (approximately
equivalent to −1.5 SD) in one or more of the primary outcome
measures
Previous brain neurosurgery, with the exception of sub-ependymal
giant cell astrocytoma removal surgery or radiosurgery 5 or more yearsv
ago
5 Calculated GFR >60 ml/min/1.73 m2, except in case of renal
impairment associated with TSC kidney disease, in which event a
calculated GFR should be ≥30 ml/min/1.73 m2
Significant haematological abnormality (i.e., haemoglobin <8 g/dl,
platelets <80,000/mm3, absolute neutrophil count <1000/mm3)
6 INR ≤1.5 (anti-coagulation permitted if target INR on stable dose of
warfarin or LMW heparin for >2 weeks at time of randomisation)
Urine protein/creatinine >0.02 g/mmol, except in case of renal
impairment associated with TSC kidney disease, in which case urine
protein/creatinine ratio should be >0.1 g/mmol for exclusion
7 Adequate liver function as shown by serum bilirubin ≤1.5 times ULN,
ALT and AST ≤2.5 times ULN
Serum creatinine >1.5 times ULN, except in cases of renal impairment
associated with TSC complication of kidneys, where serum creatinine
should be >300 μmol/L for exclusion
8 If sexually active, negative pregnancy test in females at the time of
informed consent, contraception for males and pre-menopausal
females in the study
Uncontrolled hyperlipidaemia (fasting cholesterol >300 mg/dl or
>7.75 mmol/L and fasting triglycerides >2.5 times ULN, or diabetes
with fasting serum glucose >1.5 times ULN)
9 Seizure-free or stable seizures as defined by no change in type of AEDs
in 6 months prior to full recruitment and randomisation at baseline;
doses of drugs may have been changed in the 6 months prior to
recruitment
History of myocardial infarction, angina or stroke related to
atherosclerosis, or any other significant cardiac disease, HIV
seropositivity, organ transplant, malignancy other than squamous or
basal cell skin cancer
10 Hepatitis B surface antigen-negative, hepatitis C antibody-negative Lymphangioleiomyomatosis with FEV1 < 70 % of predicted, or any
other restrictive pulmonary disease
11 All patients must be able to communicate well with the investigator, to
understand and comply with the requirements of the study, and to
understand and sign the written informed consent form
Bleeding diathesis or on oral anti-vitamin K medication other than low-
dose warfarin
12 Female patients of childbearing potential must be prepared to use two
acceptable methods of contraception (e.g., intra-uterine device plus
condom, spermicidal gel plus condom, diaphragm plus condom) from
the time of screening
Pregnancy/lactation
13 Live vaccine required during trial
14 Use of strong inhibitor of CYP3A4
15 Use of strong inducer of CYP3A4, except for anti-epileptic drugs
16 Intercurrent infection at time of randomisation
17 Inability to complete study materials (outcome measures) in English
18 History of significant trauma-related cognitive deficit
19 Impairment of gastrointestinal function or gastrointestinal disease that
may significantly alter the absorption of everolimus (e.g., pancreatic
insufficiency)
20 Known sensitivity to everolimus or other rapamycin analogues or to its
excipients
21 Inability to attend scheduled visits
Abbreviations: AED anti-epileptic drug; ALT alanine aminotransferase, AST aspartate aminotransferase, CYP3AE cytochrome P450 3AE, FEV1 forced expiratory volume
in 1 second, GFR glomerular filtration rate, INR international normalised ratio, LMW low molecular weight, mTOR mammalian target of rapamycin, TSC tuberous
sclerosis complex, ULN upper limit of normal, WASI Wechsler Abbreviated Scale of Intelligence
aPatients meeting any of the exclusion criteria will be excluded from entry into or continuation in the study unless sponsor approval is obtained
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Safety information and clinical management
Adverse events (AE) are defined as the appearance or
worsening of any undesirable sign, symptom or medical
condition occurring after starting the study drug or pla-
cebo, even if the event is not considered to be related to
the investigational medicinal product (IMP). The most
common AE are listed in Table 2, and further informa-
tion on frequency categories of adverse reactions is re-
ported in Additional file 2.
All AE will be collected, recorded and reported in ac-
cordance with good clinical practice and the require-
ments of the Medicines for Human Use (Clinical Trials)
Regulations 2004. Their severity will be graded accord-
ing to the CTCAE. Once detected, they will be treated
appropriately and monitored until resolution, unless
deemed by the investigator as not necessary and docu-
mented accordingly. Treatment may include interruption,
modification or discontinuation of study drug treatment
and changes in the frequency or nature of assessments,
hospitalisations or any other medically required interven-
tions. Recommended treatment of side effects is detailed
in Additional file 3.
Known common side effects of the IMP are listed in
the summary of product characteristics (SmPC), which
is the reference safety information (RSI) for this trial.
Any new relevant information between SmPC updates
will be issued in the form of investigator notifications.
On the basis of the approved RSI for everolimus, ex-
pected AE in patients with tuberous sclerosis are sei-
zures and haemorrhage from AML; additional expected
AE in females with lymphangioleimyomatosis complicat-
ing TSC are pneumothorax, chest infection, chylothorax
and haemoptysis.
AE the nature and severity of which are consistent
with the information set out in the SmPC for everolimus
will be considered expected. Events ongoing at study
completion will be followed as clinically indicated.
Furthermore, effects of the study drug may be influenced
by products that affect cytochrome P450 3A4 and/or P-
glycoprotein. These will be avoided wherever possible or
used with caution and documented accordingly.
Pregnancy
Eligible participants are advised that it is not recom-
mended to become or to make their partners pregnant
whilst on, and until 30 days after stopping, the study
drug. Pregnancies will be reported and documented as
appropriate, and followed to determine outcome, includ-
ing spontaneous or voluntary termination; details of the
birth; and the presence or absence of any birth defects,
congenital abnormalities or maternal and/or newborn
complications. A pregnancy in the partner of a male par-
ticipant occurring up to 3 months after stopping the
study drug will be reported to the sponsor as soon as
possible after consent to report information regarding
pregnancy outcome has been obtained from the mother.
Outcome measures
The neurocognitive measures listed in Table 3 will be
used at various study visits (see the neuropsychological
assessment schedule in Additional file 4 for full details).
Although the test battery at some visits is extensive, pa-
tients who have neurocognitive problems will complete
only the earliest stages of many tests and will therefore
complete their assessments much more quickly than the
“maximum times” listed in Table 3. A similar test battery
has been used with patients with TSC in a previous
study [14].
Study assessments
The timing of assessments required during the study is
delineated in the study assessment schedule shown in
Additional file 5. Appointments will be postponed and
rescheduled for patients who have had a generalised
tonic-clonic seizure within 48 h of scheduled neurocog-
nitive testing or a complex partial seizure within 24 h of
scheduled neurocognitive testing. At the screening visit,
background, demographic and administrative assess-
ments will be carried out which will include relevant
medical history/current medical conditions; a physical
examination; and blood laboratory examinations as per
protocol, including a hepatitis screen and a pregnancy
test. Patients will also be assessed for IQ [17], handed-
ness [18] and pre-morbid intellectual function [19]. The
clinician will also ascertain eligibility by evaluation based
on the inclusion and exclusion criteria of the study.
Following the screening visit (visit 1), eligible patients
will be scheduled for the baseline and randomisation
visit (visit 2) approximately 4 weeks later. This will be
considered week 0, and treatment will commence. As
outlined in the study assessment schedule (Additional
Table 2 Common adverse events
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file 5), patients will then be followed for 6 months, with
study visits taking place at week 2 (safety), week 4
(safety, some neurocognition), week 6 (safety), week 12
(full neurocognition) and week 24 (full neurocognition
at the end of the treatment phase). Each of these visits
will take place within 12 h after the last drug administra-
tion. A further assessment will be carried out 12 weeks
after the end of the last drug or placebo administration,
at week 36. Patients will visit the study site on the re-
quired days and may stay overnight if travelling from
afar, though no hospitalisation will be required. It is an-
ticipated that regular contact with participants and
carers will offer the opportunity to address any issues
which may contribute to attrition.
Safety assessments will include physical examinations,
vital signs and standard clinical laboratory evaluations of
haematology, blood chemistry, urinalysis, AE and serious
adverse event (SAE) monitoring at each site visit. Moni-
toring by telephone will be carried out by the clinical
trial team at 1 week after initiation of treatment and
each month thereafter during the treatment phase of the
study, unless a study visit takes place during that calen-
dar month. See Additional file 5 for a full breakdown of
the study assessment schedule.
Efficacy assessments for memory (verbal recall mem-
ory and non-verbal recall memory) will be measured
using two tests that have been validated in the U.K.
population across the age range required for this study
and for which multiple parallel forms are available as
required for retesting. Attentional/executive function
will be measured using two tests from a similarly stan-
dardised computerised battery, and another from a fur-
ther well-validated ‘pen-and-paper’ test battery.
Verbal recall memory will be assessed using the list
learning recall task [20]. Non-verbal recall memory will
be assessed using the complex figure recall task [20]. At-
tentional/executive function will be assessed using the
Stockings of Cambridge [21] planning task and the
Spatial Working Memory test [21], and also using the
dual task [22].
Attention will be assessed by using the Rapid Visual
Information Processing test, the visual search task, sus-
tained listening tasks [22] and the cancellation task [23].
Executive function will be assessed by using the non-
verbal intra-dimensional/extra-dimensional test [21] and
the verbal Controlled Oral Word Association Test/FAS
test [23]. The spatial span task will assess simple work-
ing memory. The Symptom Checklist-90-Revised [24]
will be used to assess psychological problems and symp-
toms of psychopathology and/or psychiatric issues.
The Quality of Life in Epilepsy Inventory [25] will be
used to evaluate overall quality of life. Seizure severity
will be assessed by using the Liverpool Seizure Severity
Scale [26] and a seizure diary. A carer, relative or
friend will complete the Vineland Adaptive Behaviour
Scales-II [27], the Social Responsiveness Scale – Adult
version [28] to assess any autism spectrum symptoms,
and the Social Communication Questionnaire [29]. All
scheduled safety and outcome assessments will be
done at the Clinical Research Facility at the University
Hospital of Wales, Cardiff. This facility has a dedi-
cated neurocognitive testing suite.
Data management and monitoring
Data will be captured on study-specific case report
forms (CRFs). CRFs will not constitute source data, and
Table 3 Neurocognitive outcome measures
Name of measure
Eligibility visit screening measures Wechsler Abbreviated Scale of Intelligence (four subtests) [17]
Edinburgh Handedness Inventory [18]
Primary outcome measures Complex Figure test and List Learning test from the BIRT Memory and Information Processing Battery [20]
Spatial Working Memory and Stockings of Cambridge from the CANTAB [21]
Telephone search dual task from the Test of Everyday Attention [22]
Secondary outcome measures Information Processing Battery, spatial span and attentional set-shifting (IDED) from the CANTAB [21]
Cancellation task and Verbal Fluency from the Controlled Oral Word Association Test [23]
Symptom Checklist-90-Revised [24]
Quality of Life in Epilepsy [25]
Liverpool Seizure Severity Scale [26]
Vineland Adaptive Behaviour Scales-II (survey form) [27]
Social Responsiveness Scale – Adult version [28]
Social Communication Questionnaire [29]
National Adult Reading Test [19]
Abbreviations: BIRT Brain Injury Rehabilitation Trust, CANTAB Cambridge Neurocognitive Test Automated Battery, IDED intra-dimensional/extra-dimensional
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all data entered on the CRFs will be traceable to an ori-
ginal source record (electronic or paper), either as part
of the electronic database or in the patient’s file. All data
management procedures will be detailed in the trial-
specific data management plan.
The sponsor’s monitoring standards will ensure 100 %
verification for the presence of informed consent, adher-
ence to the inclusion and exclusion criteria, documentation
of SAE, and recording of data that will be used for all pri-
mary variables. Additional checks of the consistency of the
source data with the CRFs will be performed according to
the study-specific monitoring plan. All data will be kept for
15 years, in line with the sponsor’s research governance
framework regulations for clinical research. Data will be
anonymised and stored confidentially in accordance with
the Data Protection Act 1998 on password-protected
servers maintained in the Cardiff University network.
A Data Monitoring Committee (DMC) will be estab-
lished that will consist of an independent chair and two
other independent members. The main role of the DMC
will be to safeguard the interests of the trial’s partici-
pants, review the data periodically and make recommen-
dations to the Study Steering Committee.
Statistical methods
Main analysis
All randomised participants who received at least one
dose of study drug will be included in the data ana-
lysis. Patients will be analysed according to the treat-
ment they received. We will present data descriptively
and determine effect sizes. Results will be presented
split by trial arm.
The primary outcome of this study is memory func-
tion with improved memory function classed as a 1-
SD response on any of the memory tests listed in
Table 3. A one-sample chi-square test will be used to
determine whether the proportion of patients in the
intervention group with improved recall memory at
6 months by 1 SD is at least 0.35. The effect size will
be presented alongside a 95 % CI and p value. The
proportion of patients in the control group displaying
improved functioning by 1 SD will be used to highlight
the learning effect.
Secondary analyses
Secondary outcomes will be presented descriptively at
baseline and 6 months, and effect sizes will be deter-
mined. The effect (between baseline and 6 months) of
the control and intervention arms on wider aspects of
neurocognitive function, seizures and daily life will be
similarly assessed. Secondary analyses will consider both
the primary and secondary outcome measures as dimen-
sions of memory function as continuous variables rather
than just the proportion of improved patients over time.
In further modelling, we will use repeated-measures
multivariate analysis of variance to model patterns of
functioning over time at baseline and at 3 and 6 months.
In these analyses, we will compare the scores from each
neurocognitive test at 6 months between the interven-
tion and control arms and will adjust for the balancing
factors. The result will be presented as the (adjusted) dif-
ference in test outcomes between the intervention and
control groups, along with 95 % CI and p value. The use
of composite measures of these scales will be explored.
Discussion
This proof-of-principle trial will be the first to determine
the effect sizes of treatment with everolimus or placebo
for 6 months for recall memory and executive function
in adults with tuberous sclerosis. The goal is to provide
evidence for whether larger trials for this indication in
an adult population are appropriate.
The findings of this study will advance current know-
ledge in terms of understanding and treatment of tuber-
ous sclerosis. Participants who receive this intervention
have the potential for an amelioration of the neurocogni-
tive deficits associated with tuberous sclerosis. Add-
itional potential benefits exist, as mTOR inhibitors have
been shown to reduce the size of renal AMLs that are
present in most adults with tuberous sclerosis [11, 13]
and also to improve the characteristic facial rash (facial
angiofibromatosis) [30]. Wider potential benefits to soci-
ety include reduced demand on carers and on health
and social care services, as well as insights into the
mechanistic basis for these problems in patients with
tuberous sclerosis and potentially other patient groups.
Trial status
The trial is sponsored by Cardiff University and is cur-
rently ongoing and open to recruitment. The manuscript
of this report was drafted according to version 9.0 (15
January 2015) of the trial protocol. The protocol was
written according to the SPIRIT statement. The final re-
port will be written in accordance with the Consolidated
Standards of Reporting Trials (CONSORT) statement.
Additional files
Additional file 1: SPIRIT checklist of key issues addressed in the trial
protocol. (PDF 59 kb)
Additional file 2: Frequency categories of adverse reactions reported in
the pooled analysis considered for the safety pooling. (PDF 76 kb)
Additional file 3: The recommended treatment of side effects that may
occur when receiving everolimus. (PDF 41 kb)
Additional file 4: Neuropsychological assessment schedule of all
neuropsychological assessments to be carried out as part of the trial.
(PDF 53 kb)
Additional file 5: Study assessment schedule of all assessments to be
carried out as part of the trial. (PDF 46 kb)
Randell et al. Trials  (2016) 17:398 Page 8 of 10
Abbreviations
AE, adverse events; AED, anti-epileptic drug; ALT, alanine aminotransferase; AML,
angiomyolipoma; AST, aspartate aminotransferase; BIRT, Brain Injury Rehabilita-
tion Trust; CANTAB, Cambridge Neurocognitive Test Automated Battery; CON-
SORT, Consolidated Standards of Reporting Trials; CRN, Clinical Research
Network; CTCAE, Common Terminology Criteria for Adverse Events; CYP3AE,
cytochrome P450 3AE; DMC, Data Monitoring Committee; DTI MR, diffusion ten-
sor imaging magnetic resonance imaging; FEV1, forced expiratory volume in
1 second; GFR, glomerular filtration rate; IDED, intra-dimensional/extra-dimen-
sional; IMP, investigational medicinal product; INR, international normalised ratio;
LMW, low molecular weight; mTOR, mammalian target of rapamycin; mTORC1,
mammalian target of rapamycin complex 1; PIS, patient information sheet; RSI,
reference safety information; SAE, serious adverse event; SmPC, summary of
product characteristics; SPIRIT, Standard Protocol Items: Recommendations for
Interventional Trials; SRS-A, Social Responsiveness Scale – Adult version; TAND,
tuberous sclerosis-associated neuropsychiatric disorders; TSA, Tuberous Sclerosis
Association; TSC, tuberous sclerosis complex; ULN, upper limit of normal; WASI,
Wechsler Abbreviated Scale of Intelligence
Acknowledgements
The authors acknowledge the funder of this study, Novartis Pharmaceuticals UK
Ltd., along with support from the Tuberous Sclerosis Association (TSA) and Wales
Gene Park. The authors also acknowledge the contribution of the Trial Steering
Committee members, namely Professor David Franz, Perry James and Dr. Kate
Brain. The authors extend special thanks to the Clinical Research Facility
Staff at University Hospital of Wales and the study administrator.
Acknowledgements are due to the study participants and their families.
The authors also acknowledge Dr. Deborah McCartney for her
contribution to the neurocognitive aspects of trial design.
Authors’ contributions
ER led the writing of the manuscript, contributed to the protocol development,
and managed the set-up of the trial and the initial recruitment period. JRS is the
Chief Investigator who led the study design, funding application and manage-
ment of the study together with PJdV, DMD and KH. KH led the statistical design
for the study. RM contributed to the study design, funding application, study man-
agement and study implementation. RCJ contributed to the study design and
management as well as the statistical component of the study. AS contributed to
recruitment and medical assessment of patients, monitoring of patients, liaison
with patients’ local medical teams, and management of AEs. EM and LS under-
took neurocognitive assessments. MS contributed to study design and manage-
ment. EOJ and CD undertook study management and contributed to the
protocol and intervention delivery. NK and LA contributed to data management
and recruitment. All authors contributed to, read and approved the final
manuscript.
Competing interests
This trial is partly funded by Novartis Pharmaceuticals. JRS and PJdV have
received travel refunds and lecture honoraria from Novartis. DMD and AS
receive payment for work in a tuberous sclerosis specialist clinic, for which
their employers are refunded by Novartis Pharmaceuticals. PJdV is a member
of the study steering group of three phase III clinical trials (EXIST-1, EXIST-2
and EXIST-3) sponsored by Novartis and is a scientific advisory board mem-
ber of the TOSCA Natural History Study, sponsored by Novartis. The other au-




1South East Wales Trials Unit, Centre for Trials Research, Cardiff University, 7th
floor Neuadd Meirionnydd, Heath Park, Cardiff CF14 4YS, UK. 2Institute of
Cancer & Genetics, Cardiff University School of Medicine, Institute of Medical
Genetics Building, Heath Park, Cardiff CF14 4XN, UK. 3Department of Clinical
Neuropsychology, Cardiff and Vale University Health Board (University
Hospital of Wales), Heath Park, Cardiff CF14 4XW, UK. 4School of Psychology,
Aras an Phiarsaigh, Trinity College, Dublin 2, County Dublin, Ireland. 5Division
of Child & Adolescent Psychiatry, Department of Psychiatry and Mental
Health, University of Cape Town, 46 Sawkins Road, Rondebosch 7700, South
Africa.
Received: 12 January 2016 Accepted: 18 June 2016
References
1. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl
J Med. 2006;355(13):1345–56.
2. de Vries PJ, Whittemore VH, Leclezio L, Byars AW, Dunn D, Ess KC, et al.
Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the
TAND Checklist. Pediatr Neurol. 2015;52(1):25–35.
3. Curatolo P, Moaveroa R, de Vries PJ. Neurological and neuropsychiatric
aspects of tuberous sclerosis complex. Lancet Neurol. 2015;14(7):733–45.
4. Hunt A. Tuberous sclerosis: a survey of 97 cases. III: Family aspects. Dev Med
Child Neurol. 1983;25(3):353–7.
5. de Vries PJ, Howe CJ. The tuberous sclerosis complex proteins – a GRIPP on
cognition and neurodevelopment. Trends Mol Med. 2007;13(8):319–26.
6. Makki MI, Chugani DC, Janisse J, Chugani HT. Characteristics of abnormal
diffusivity in normal-appearing white matter investigated with diffusion
tensor MR imaging in tuberous sclerosis complex. AJNR Am J Neuroradiol.
2007;28(9):1662–7.
7. Huang J, Manning BD. The TSC1–TSC2 complex: a molecular switchboard
controlling cell growth. Biochem J. 2008;412(2):179–90.
8. Yang J, Kalogerou M, Samsel PA, Zhang Y, Griffiths DF, Gallacher J, et al. Renal
tumours in a Tsc2+/− mouse model do not show feedback inhibition of Akt
and are effectively prevented by rapamycin. Oncogene. 2015;34(7):922–31.
9. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, et al.
Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis.
Nat Med. 2008;14(8):843–8.
10. Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, et al. Response of a
neuronal model of tuberous sclerosis to mammalian target of rapamycin
(mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved
survival and function. J Neurosci. 2008;28(21):5422–32.
11. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, et al.
Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
N Engl J Med. 2010;363(19):1801–11.
12. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al.
Efficacy and safety of everolimus for subependymal giant cell astrocytomas
associated with tuberous sclerosis complex (EXIST-1): a multicentre,
randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125–32.
13. Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney
DL, et al. Sirolimus therapy in tuberous sclerosis or sporadic
lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):200–3.
14. Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, et al.
Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic
lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17(12):4071–81.
15. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E,
et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex
or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised,
double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817–24.
16. Fleming TR. One-sample multiple testing procedure for phase II clinical
trials. Biometrics. 1982;38(1):143–51.
17. Wechsler D. Manual for the Wechsler Abbreviated Scale of Intelligence. San
Antonio, TX: Psychological Corporation; 1999.
18. Oldfield RC. The assessment and analysis of handedness: the Edinburgh
inventory. Neuropsychologia. 1971;9(1):97–113.
19. Nelson HE. The National Adult Reading Test (NART): test manual. Windsor,
UK: NFER-Nelson; 1982.
20. Coughlan AK, Oddy MJ, Crawford JR. BIRT Memory and Information
Processing Battery (BMIPB). London: Brain Injury Rehabilitation Trust; 2007.
21. Cambridge Neuropsychological Test Automated Battery (CANTAB).
Cambridge, UK: Cambridge Cognition; 2008.
22. Robertson IH, Ward T, Ridgeway V, Nimmo-Smith I. Test of Everyday
Attention (TEA). San Antonio, TX: Psychological Corporation; 1994.
23. Benton AL, de Hamsher SK, Sivan AB. Multilingual Aphasia Examination. 2nd
ed. Iowa City, IA: AJA Associates; 1983.
24. Derogatis LR. Symptom Checklist-90-Revised. San Antonio, TX: Psychological
Corporation; 1975.
25. Vickrey BG. Quality of Life in Epilepsy Inventory (QOLIE). Santa Monica, CA:
RAND Health; 1993.
26. Baker GA, Smith DF, Jacoby A, Hayes JA, Chadwick DW. Liverpool Seizure
Severity Scale revisited. Seizure. 1998;7(3):201–5.
Randell et al. Trials  (2016) 17:398 Page 9 of 10
27. Sparrow SS, Cicchetti DV, Balla DA. Vineland Adaptive Behavior Scales
(Vineland II). 2nd ed. San Antonio, TX: Psychological Corporation; 2005.
28. Constantino JN. Social Responsiveness Scale – Adult version (SRS-A). Los
Angeles: Western Psychological Services; 2005.
29. Rutter M, Bailey A, Lord C. Social Communication Questionnaire (SCQ). Los
Angeles: Western Psychological Services; 2003.
30. Hofbauer GF, Marcollo-Pini A, Corsenca A, Kistler AD, French LE, Wüthrich
RP, et al. The mTOR inhibitor rapamycin significantly improves facial
angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol.
2008;159(2):473–5.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Randell et al. Trials  (2016) 17:398 Page 10 of 10
